0OIR Decision To Complete Share Split At A Ratio Of 1:20
16 Marzo 2022 - 7:17PM
UK Regulatory
TIDMALK TIDMB
At the annual general meeting of ALK-Abelló (ALKB:DC / OMX: ALK
B / AKABY / AKBLF) on 16 March 2022, the general meeting adopted to
amend the denomination of each share's nominal value from DKK 10 to
DKK 0.50 or multiples thereof. The amendment of the shares' nominal
value enables the Board of Directors of ALK-Abelló A/S to carry out
a share split.
On that basis, the Board of Directors has decided to complete a
share split at a ratio of 1:20 entailing that each existing share
of a nominal value of DKK 10 will be split into 20 new shares of a
nominal value of DKK 0.50 each. Following the share split, the
company's share capital of DKK 111,411,960 will be divided into
18,415,200 A shares, 1,841,520 AA shares and 202,567,200 B shares,
each having a nominal value of DKK 0.50. Upon completion of the
share split, each A share and AA share of a nominal value of DKK
0.50 shall have 10 votes and each B share of a nominal value of DKK
0.50 shall have one vote.
The planned schedule for completion of the share split of the
company's B shares listed at Nasdaq Copenhagen will be as
follows:
-- 25 March 2022: Last day of trading at Nasdaq Copenhagen via the existing
ISIN code DK0060027142
-- 28 March 2022: First day of trading at Nasdaq Copenhagen via the new ISIN
code DK0061802139
-- 29 March 2022: The new ISIN code and face value (nominal denomination) of
the B shares are registered with VP Securities A/S (Euronext)
Following the share split, the ticker symbol for ALK-Abelló's B
shares will continue to be "ALK B". The company's A and AA shares
are not listed and, consequently, new ISIN codes etc. are not
created for these shares.
ALK-Abelló A/S
For further information, please contact:
Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile
+45 2261 2525
Media: Jeppe Ilkjær, mobile +45 3050 2014
About ALK
ALK is a global specialty pharmaceutical company focused on
allergy and allergic asthma. It markets allergy immunotherapy
treatments and other products and services for people with allergy
and allergy doctors. Headquartered in Hørsholm, Denmark, ALK
employs around 2,600 people worldwide and is listed on Nasdaq
Copenhagen. Find more information at www.alk.net.
Attachment
-- FM_06_21UK_16032022
https://ml-eu.globenewswire.com/Resource/Download/b97e77ce-8c52-44fa-8958-6d242f3e94ac
(END) Dow Jones Newswires
March 16, 2022 14:17 ET (18:17 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Grafico Azioni Alkemy Capital Investments (LSE:ALK)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Alkemy Capital Investments (LSE:ALK)
Storico
Da Lug 2023 a Lug 2024